Fortrea Increases Patient Access Capabilities and Cold Chain Expertise with FortreaRx™ Expansion
- None.
- None.
The expansion of Fortrea's specialty pharmacy, FortreaRx, notably impacts the pharmaceutical supply chain by providing a critical link between manufacturers and patients. The increase in operational space and enhanced cold chain capabilities are significant because they address a growing demand for specialized logistics in the delivery of temperature-sensitive medications. Cold chain storage is essential for many biologics and advanced therapies that require strict temperature control to maintain efficacy.
This expansion also reflects a trend in the pharmaceutical industry towards patient-centric services. By focusing on patient assistance programs, Fortrea is catering to a market niche for individuals who are uninsured or underinsured, which could potentially improve medication adherence and outcomes. Moreover, the scalability of the solutions implies that Fortrea is positioning itself to handle an increasing volume of prescriptions, which could lead to stronger partnerships with pharmaceutical manufacturers.
The strategic expansion of FortreaRx aligns with the broader industry's shift towards personalized healthcare and patient access. This business move is likely to appeal to pharmaceutical companies seeking to enhance patient support and adherence through comprehensive patient assistance programs. From a market perspective, the enhanced shipping solutions and increased prescription handling capacity may offer Fortrea a competitive advantage, potentially translating into increased market share and stronger client relationships within the CRO sector.
Furthermore, as healthcare costs continue to rise, programs that offer cost savings to patients are increasingly valuable. FortreaRx's consultative approach to prescription management could result in improved patient satisfaction and loyalty, which are critical metrics for success in the healthcare sector. The financial implications for Fortrea could be significant if these enhanced services lead to new contracts with pharmaceutical companies or expansion of existing ones.
The emphasis on patient assistance programs by FortreaRx is indicative of a response to a pressing health policy issue: access to medications for vulnerable populations. By doubling its operational space and offering robust distribution capabilities, FortreaRx is not only enhancing its commercial proposition but also addressing a societal need. This initiative could be seen as a positive contribution to public health, potentially reducing the economic burden on the healthcare system by improving access to medications for those without adequate insurance coverage.
Moreover, the implications of such expansions may involve regulatory considerations, particularly with the licensing across all 50 states and U.S. territories. This demonstrates compliance with a complex web of state and federal regulations, which is crucial for maintaining the integrity of the pharmaceutical supply chain and ensuring patient safety.
Fortrea’s non-commercial specialty pharmacy expansion delivers flexible, scalable solutions to customers and life-changing medications direct to patients
DURHAM, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the opening of its expanded non-commercial specialty pharmacy, FortreaRx™, located in Lake Mary, Florida, which offers advanced patient access solutions across the United States, including ambient and cold-chain distribution capabilities and expertise.
Licensed in all 50 states and U.S. territories, FortreaRx delivers flexible, scalable solutions that meet the specific needs of its customers while providing medications to patients who may otherwise not have access to them. Non-commercial specialty pharmacies, like FortreaRx, provide these solutions on behalf of their pharmaceutical manufacturer customers and are uniquely positioned to serve as a bridge between pharmaceutical manufacturers and patients who meet the manufacturer requirements for prescription assistance.
Since FortreaRx’s inception in late 2008, Fortrea has pioneered non-commercial specialty pharmacy services, focusing exclusively on the distribution of free-goods products as an integrated component of pharmaceutical manufacturer-sponsored patient assistance programs (PAP) designed to expand access to therapy for qualified patients with no health insurance or those who are underinsured. The FortreaRx 40,000-square-foot facility doubles its operational space and bolsters its capabilities, delivering:
- 1,800 square feet of ambient storage
- 6,000+ square feet of cold chain storage with more than 85 percent of prescriptions filled by FortreaRx requiring this unique handling
- Greater processing and fulfillment space for up to 18,000 prescriptions daily
- Enhanced shipping solutions with options for overnight, expedited and 2-day deliveries
"Fortrea’s well-established patient services offerings, combined with the expanded capabilities of FortreaRx, deliver an end-to-end approach, from early clinical stages to post-market delivery, ensuring a comprehensive and personalized experience for patients," said Bill Nolan, vice president and global head of Patient Access at Fortrea. "From our expertise in broad-range disease states to our unwavering commitment to patient assistance, Fortrea excels at delivering timely and impactful solutions to our pharmaceutical sponsors that strive to reduce patient and provider challenges by streamlining enrollment processes and by offering full integration with broader patient support initiatives."
FortreaRx’s call center hub of case managers seamlessly manages patient inquiries, counseling and data verification of prescriptions. Fortrea’s patient access team helps patients and providers understand and navigate the complexities of coverage while removing obstacles to get medication to patients.
FortreaRx delivers efficient, consultative and cost-effective solutions for manufacturer prescription programs typically resulting in significant yearly savings for patients.
For more information about FortreaRx and its services, please visit Fortrea.com.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology-enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team of about 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter) @Fortrea.
Fortrea Contacts:
Fortrea Media: Galen Wilson – 703-298-0802, media@fortrea.com
Fortrea Media: Kate Dillon – 646-818-9115, kdillon@prosek.com
FAQ
What is the name of the expanded non-commercial specialty pharmacy by Fortrea in Lake Mary, Florida?
Where is FortreaRx™ located?
What capabilities does FortreaRx™ offer?
What percentage of prescriptions filled by FortreaRx require cold chain storage?
What is the focus of FortreaRx since its inception in 2008?
